Starpharma (ASX:SPL) launches antiviral nasal spray in Europe

May 6th, 2021

The Market Herald reported on Starpharma's launch of VIRALEZE™  in Europe. Read the full article here.

• Starpharma’s (SPL) antiviral nasal spray is now available for purchase by consumers in Europe via the company’s online store
• VIRALEZE is a broad spectrum antiviral nasal spray, which studies have shown can inactivate more than 99.9 per cent of coronavirus pathogens within one minute
• The product is already available online in the U.K. and through Lloyds Pharmacy’s 1400 stores, with the company now pursuing avenues to provide rapid access for VIRALEZE in India
• Starpharma shares are up 3.93 per cent, trading at $1.85

Australian company develops a $27 anti-viral nasal spray that 'deactivates' Covid - and it's being used right across the UK

May 4th, 2021

Eliza McPhee for Daily Mail Australia reported: An Australian biotech company has joined the fight against coronavirus by launching an anti-viral nasal spray that's already available in the UK. Read the article here. 

• Biotech company Starpharma has launched anti-viral nasal spray in the UK
• It acts as a barrier to coronavirus, trapping it in the nose and inactivating virus
• Spray best used once every six hours for up to 30 days, CEO Jackie Fairley says
• Melbourne-based company says it has plans to launch product soon in Australia 

VIRALEZE™ on 7NEWS Australia

May 1st, 2021

VIRALEZE™ was featured on 7NEWS Australia in an interview with Starpharma CEO Dr Jackie Fairley. The antiviral nasal spray is now available online and instore at LloydsPharmacy in the UK with EU launch to follow in the coming weeks. Watch the playback on 7plus (~32.28 min.) or YouTube below.

Starpharma (ASX:SPL) spends March quarter developing VIRALEZE

Apr 28th, 2021

Starpharma featured in The Market Herald following the announcement of Starpharma's Quarterly Cashflow and Activities Report. Read more here. 

GlaxoSmithKline hoping to deliver Australia’s next COVID treatment

Apr 16th, 2021

Starpharma featured in The Sydney Morning Herald's daily COVID-19 update, as reported by Emma Koehn: ASX-listed companies have pivoted swiftly towards virus treatments and preventative in the past year, including Melbourne-based Starpharma which successfully brought a nasal spray to market in the UK last month. Read more here. 

Aussie virus killer not to be sneezed at

Apr 11th, 2021

The Australian interviewed Dr Jackie Fairley, Starpharma CEO, about the recent launch of Viraleze in the UK. "As the nation hyperventilates over a delay in the vaccine rollout, Starpharma is rolling out a new line of defence against the coronavirus in global markets." Read more here. (Behind paywall)

LloydsPharmacy launches nasal spray designed to fight coronavirus

Mar 30th, 2021

The Grocer reported on the launch of VIRALEZE in LloydsPharmacy across the UK. It launches online this week, ahead of an in-store rollout from April. Read more here.

Covid antiviral nasal spray available from Lloyds

Mar 30th, 2021

Pharmacy Magazine UK reported on the launch of VIRALEZE in the UK. A novel nasal spray available exclusively from LloydsPharmacy. The UK will be the first country to launch this product. Read more here.

Lloyds Pharmacy offering first-ever Covid nasal spray Viraleze that 'blocks 99.9% of germs'

Mar 30th, 2021

CambridgeshireLive featured news of the VIRALEZE launch in the UK. A groundbreaking Covid nasal spray called Viraleze is now available to buy online. Lloyds Pharmacy is rolling out the UK's first-ever nasal spray specifically designed to fight coronavirus. Read more here. 

Sky News reports on launch of VIRALEZE™

Mar 29th, 2021

Sky News interviewed Starpharma CEO Dr Jackie Fairley about the UK launch of VIRALEZE™ at LloydsPharmacy. Dr George Kinghorn, Infectious Disease Adviser and former Clinical Director of the Sheffield Teaching Hospitals NHS Foundation Trust was also interviewed for further commentary on VIRALEZE™.

Starpharma to launch anti-COVID nasal spray with major UK pharmacy chain

Mar 25th, 2021

Business News Australia reported VIRALEZE will be stocked by LloydsPharmacy in the UK. It will first be made available at LloydPharmacy's online store and is expected to be instore in April. Read more here.

Aussie biotech Starpharma signs deal to sell COVID nose spray in Britain

Mar 25th, 2021

The Age reported Australian biotech Starpharma is taking its COVID-fighting antiviral nasal spray to the world, signing a deal with UK chemist chain LloydsPharmacy to sell the product in Britain as the country emerges from lockdown. Read more here. 

Starpharma (ASX:SPL) reports DEP HER2-lutetium shows potent anticancer effect

Mar 16th, 2021

Finance News Network reported that Starpharma's second radiopharmaceutical candidate, DEP HER2-lutetium, achieved potent and durable anticancer activity, with complete tumour regression, outperforming Herceptin labelled with lutetium, in a breast cancer model. Read more here. 

Starpharma (ASX:SPL) shares rise on breast cancer development

Mar 16th, 2021

The Market Herald reported that Starpharma's second radiopharmaceutical candidate, DEP HER2-lutetium, had achieved anti-cancer activity in breast cancer, and that the drug outperformed Herceptin, a treatment for a type of breast cancer called HER2 positive. Read more here. 

Starpharma Up With News, Down With None; Timing Entry Makes Sense

Feb 25th, 2021

Seeking Alpha, a financial market portal featured an update Starpharma, including the European registration of its VIRALEZE™ antiviral nasal spray. To read the full article click here.

Channel 7 News reports Starpharma's VIRALEZE has been registered in the UK/Europe

Feb 23rd, 2021

Channel 7 News (Melbourne) reports Starpharma's VIRALEZE™ has been registered in the UK/Europe. Watch here. 

Starpharma signs research agreement with MSD

Feb 12th, 2021

The Market Herald reported that Starpharma signed a Research Agreement with Merck & Co., Inc., Kenilworth NJ USA for dendrimer-based Antibody Drug Conjugates (ADCs) utilising Starpharma’s proprietary DEP® technology. Read more here. 

Ausbiz interviews Starpharma CEO Dr Jackie Fairley

Feb 10th, 2021

Finance and market news website AusBiz interviewed Starpharma CEO Dr Jackie Fairley to discuss the global expansion of AstraZeneca’s clinical trial for AZD0466 and their multi-product DEP® licence with Starpharma. She also spoke about the upcoming launch of VIRALEZE in Europe. Watch the interview here.

Aussie condom antiviral recruited for Covid-19 fight

Feb 4th, 2021

The Australian interviewed Starpharma CEO Dr Jackie Fairley regarding Starpharma’s plans for the European launch of VIRALEZE™ antiviral nasal spray. Read article here.

Australian-developed COVID nasal spray set to land in Europe

Feb 4th, 2021

Biotech Dispatch reported on Starpharma's launch plans for VIRALEZE™ in Europe. Read the full article here.